Home

Prevention

Alzheimer's Disease

Read time: 2 min

Addressing challenges of dosage and administration in the development of disease-modifying therapy

Challenges in the development of disease-modifying therapy for Alzheimer’s disease (AD)...

Read time: 4 min

Early intervention in schizophrenia may improve long-term outcome

Schizophrenia may not be as disabling if identified and treated early, resulting in many benefits...

Bipolar, Schizophrenia

Read time: 4 min

Dopamine synthesis is the common factor in genetic and environmental risks in schizophrenia

Excessive striatal dopamine synthesis was the common thread that Robin Murray (Institute of...

Alzheimer's Disease

Read time: 3 min

Congress highlights

Essential elements for Alzheimer’s disease clinical trials

Stronger links between novel agents and their targets, more precise selection of patients, and...

Read time: 4 min

Improved cognition and insight into thinking: can we help these to be transferred to everyday life?

There’s ‘thinking’, and there’s ‘thinking about thinking’....

Read time: 3 min

Bouncing back - Resilience in schizophrenia

Can we improve resilience in patients with schizophrenia to help recovery? Resilience is...

Read time: 4 min

GABA dysfunction – preclinical and clinical imaging perspectives in schizophrenia

The association between abnormal interneuronal function and neuropsychiatric conditions is...

Read time: 1 min

Light in the darkness: Combating the mid-winter blues

Social, cultural, and even climatic factors can make the winter holidays particularly difficult for...

Depression, Schizophrenia

Read time: 2 min

Congress highlights

Sexual side-effects – let’s talk!

Sexual side-effects, sometimes experienced by patients during treatment, are not only debilitating...

Read time: 3 min

Congress highlights

Links between insomnia and depression: can treating one problem also improve the other?

Follow-up of people with insomnia shows that 75% still have the problem a year later. During that...

Alzheimer's Disease

Read time: 3 min

Congress highlights

Images of trouble ahead: multimodal assessment of Alzheimer’s Disease

The three major neuroimaging biomarkers – structural MRI, FDG-PET, and amyloid PET –...

Read time: 3 min

Congress highlights

Coming soon….Updated APA guideline on schizophrenia

Practice guidelines assimilate the evidence-base and so help support daily clinical decision-making...

Country selection

We are registering that you are located in Brazil - if that's correct then please continue to Progress in Mind Brazil

Not located in Brazil?
Go to a different regional HUB

Continue to Progress in Mind Continue to Progress in Mind Brazil Continue to Progress in Mind Spain Continue to Progress in Mind Italy Continue to Progress in Mind

You are leaving Progress in Mind

Continue to

Cancel

Hello
Please confirm your email

We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.

The information on this site is exclusively intented for health care professionals.

All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.

Accept

Decline

Congress

Register for access to Progress in Mind in your country